Ludwig Cancer Research

Immunotherapy Market Value Grows as the Treatments Gains Widespread Importance

Retrieved on: 
Thursday, September 13, 2018
Cancer, RTT, Medicine, Clinical medicine, Cancer treatments, Immunotherapy, Breast cancer, Cancer research, Ludwig Cancer Research

The increasing spending on R&D activities for cancer immunotherapy, growing occurrence of cancer and the rise in approvals for the clinical trials are the main drivers of the market.

Key Points: 
  • The increasing spending on R&D activities for cancer immunotherapy, growing occurrence of cancer and the rise in approvals for the clinical trials are the main drivers of the market.
  • Cancer immunotherapy is one of the treatment types for cancer and has gained widespread importance in recent years.
  • The lung cancer and breast cancer segments are expected to have market size of USD 22.3 Billion and USD 18.9 Billion respectively by 2025.
  • Therapies that manipulate NR2F6 also show potential to act as cancer stem cell differentiators, transforming cancer stem cells into normal cells.

Polaris Announces Dr. Chi Van Dang Joining its Scientific Advisory Board

Retrieved on: 
Monday, July 9, 2018
Ludwig Cancer Research, Health

SAN DIEGO, July 9, 2018 /PRNewswire/ --Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced that Chi Van Dang, M.D., Ph.D. has joined its Scientific Advisory Board.

Key Points: 
  • SAN DIEGO, July 9, 2018 /PRNewswire/ --Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced that Chi Van Dang, M.D., Ph.D. has joined its Scientific Advisory Board.
  • This supports the hypothesis that disrupting cancer cells' altered metabolism pathways could be an effective approach to treating cancer.
  • Dr. Dang is the Scientific Director of the Ludwig Institute for Cancer Research.
  • He is a member of the National Academy of Medicine (Institute of Medicine), American Academy of Arts & Sciences, and chairs the National Cancer Institute's Board of Scientific Advisors.

PhoreMost and NeoPhore Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme

Retrieved on: 
Friday, April 27, 2018
Medicine, Clinical medicine, Immunotherapy, Virotherapy, Cancer immunotherapy, Cancer, Ludwig Cancer Research

The companies are partners on a grant titled, "A novel small molecule approach to enhance cancer immunotherapy."

Key Points: 
  • The companies are partners on a grant titled, "A novel small molecule approach to enhance cancer immunotherapy."
  • NeoPhore and PhoreMost are both headquartered in Cambridge UK, and NeoPhore was formed as a PhoreMost spin-out following investment of 3 million from Sixth Element Capital.
  • NeoPhore CEO Jeff Roix said: "We created NeoPhore to accelerate development of a totally new approach for cancer immunotherapy and welcome the support of the Innovate UK award to recognise and promote that business objective.
  • NeoPhore, based in Cambridge, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system.